ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Files An 8-K Regulation FD Disclosure

Item7.01

On November17, 2016, ZIOPHARM Oncology, Inc., or the Company,
will conduct an investor webcast summarizing clinical and
nonclinical data from its multi-center Phase 1 study for its
Ad-RTS-hIL-12 orally-administered veledimex product candidate in
patients with recurrent or progressive glioblastoma, or GBM, or
Grade III malignant glioma, a form of brain cancer, presented at
the 21^st Annual
Scientific Meeting and Education Day of the Society for
Neuro-Oncology (SNO), being held November17 20, 2016 in
Scottsdale, Arizona. A copy of the presentation is furnished as
Exhibit 99.2 to this Current Report on Form 8-K.

The information in Item7.01 of this Current Report on Form 8-K,
including the information contained in the presentation furnished
as Exhibit 99.2, is intended to be furnished and shall not be
deemed filed for purposes of Section18 of the Securities Exchange
Act of 1934, as amended, and is not incorporated by reference
into any of the Companys filings, whether made before or after
the date hereof, regardless of any general incorporation language
in any such filing.

On November17, 2016, the Company issued a press release
announcing its upcoming presentation of clinical and nonclinical
data from its multi-center Phase 1 study for its Ad-RTS-hIL-12
orally-administered veledimex product candidate in patients with
recurrent or progressive GBM, or Grade III malignant glioma, a
form of brain cancer, at the 21^st Annual Scientific Meeting and
Education Day of the Society for Neuro-Oncology (SNO), being held
November17 20, 2016 in Scottsdale, Arizona. The full text of the
press release is filed as Exhibit 99.1 to this Current Report on
Form 8-K and is incorporated herein by reference.

2

About ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)

ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex. The Company’s Ad-RTS-IL-12 + veledimex has been evaluated in two Phase II studies, the first for the treatment of metastatic melanoma, and the second for the treatment of unresectable recurrent or metastatic breast cancer. It has initiated the Phase I study for malignant glioma. The Company has completed the Phase II monotherapy studies in melanoma and breast cancer using Ad-RTS-IL-12 + veledimex. It has initiated a Phase Ib/II study of Ad-RTS-hIL-12 + veledimex following chemotherapy for the treatment of patients with locally metastatic breast cancer. Its initial drug candidate being developed using the synthetic immuno-oncology platform is Ad-RTS-IL-12 + veledimex.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Recent Trading Information

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) closed its last trading session down -0.73 at 6.87 with 2,944,131 shares trading hands.